Pharmacy

AHA Survey on 340B Rebate Model Closes Jan. 10

What’s happening: The American Hospital Association (AHA) is asking hospitals to complete a survey by Jan. 10 to help it understand how a 340B rebate model would impact 340B member hospitals. 

What else to know: Completing this 10-question survey will help AHA understand the financial, operational, and patient impacts that a rebate model — such as the one Johnson & Johnson sought to implement this year — would have on your hospital or health system.  

DEA, HHS Extend Telehealth Prescribing Flexibilities

What’s happening: The U.S. Drug Enforcement Administration (DEA) and federal Department of Health and Human Services (HHS) extended existing waiver flexibilities for prescribing controlled substances via telemedicine through Dec. 31, 2025. 

What else to know: This is the third extension.  

Johnson & Johnson Halts Proposed 340B Rebate Model

What’s happening: Johnson & Johnson will stop its plan that would have required hospitals participating in the 340B drug discount program to purchase Stelara and Xarelto at full price and apply for a rebate instead of receiving full discounts upfront.  

What else to know: The Health Resources and Services Administration (HRSA) notified J&J it would be kicked out of the 340B Drug Pricing Program if it did not halt implementation.  

Ask Reps. to Sign Letter Opposing 340B Program Changes

What’s happening: A bipartisan group of U.S. representatives is leading a letter to U.S. Health and Human Services (HHS) Secretary Xavier Becerra about efforts by Johnson & Johnson (J&J) to undermine the 340B Drug Discount Program.   

What else to know: Hospital leaders should call or email their U.S. representative and urge them to sign on to the letter by Sept. 27.